| Literature DB >> 24732155 |
Alan H Maurer1, Philip Elsinga, Stefano Fanti, Binh Nguyen, Wim J G Oyen, Wolfgang A Weber.
Abstract
Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. (99m)Tc-etarfolatide, a (99m)Tc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.Entities:
Keywords: 99mTc-etarfolatide; SPECT; SPECT/CT; folate receptor; imaging
Mesh:
Substances:
Year: 2014 PMID: 24732155 DOI: 10.2967/jnumed.113.133074
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 10.057